Recent Securities Litigations

Cassava Sciences Inc. Common Stock (NASDAQ: SAVA)

Company Name:Cassava Sciences Inc. Common Stock
Stock Symbol:NASDAQ: SAVA
Class Period Start:09/14/2020
Class Period End (inclusive):08/27/2021

The Complaint alleges that, throughout the Class Period, Defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the scientific data supporting Cassava Sciences’ claims for simulfilam’s efficacy had been overstated; (ii) the scientific data supporting Cassava Sciences’ claims for simulfilam’s efficacy were biased; and (iii) as a result, defendants’ positive statements during the Class Period about Cassava Sciences’ business metrics and financial prospects and the likelihood of U.S. Food Drug Administration (“FDA”) approval were false and misleading and/or lacked a reasonable basis.